Covid-19 Research


  • Page views 2511
  • PDF Downloads 2218

ISSN: 2766-2276
> Biology. 2020 October 14;1(6):216-218. doi: 10.37871/jbres1146.
Review Article

Remdesivir Research Progress: An Overview of the Emerging Evidence

Aamir Jalal Al Mosawi1,2*

1Advisor in Pediatrics and Pediatric Psychiatry Children Teaching Hospital of Baghdad Medical City
2Head, Iraq Headquarter of Copernicus Scientists International Panel Baghdad, Iraq
*Corresponding author: Aamir Jalal Al Mosawi, Advisor in Pediatrics and Pediatric Psychiatry Children Teaching Hospital of Baghdad Medical City, Iraq, Tel: +009-647-703-930-834; E-mail:
Received: 08 October 2020 | Accepted: 09 October 2020 | Published: 14 October 2020
How to cite this article: Al Mosawi AJ. Remdesivir Research Progress: An Overview of the Emerging Evidence. J Biomed Res Environ Sci. 2020 Oct 14; 1(6): 216-218. doi: 10.37871/jbres1146, Article ID: JBRES1146
Copyright:© 2020 Al Mosawi AJ, Distributed under Creative Commons CC-BY 4.0.

There has been an increasing interest in remdesivir research within the scientific medical community because of the emerging evidence suggesting its beneficial role in patients with COVID‑19. Remdesivir which can be given intravenously and not orally has an anti-viral against several RNA viruses. Remdesivir has an in vitro antiviral activity against filoviruses, arenaviruses, and coronaviruses including circulating human coronaviruses HCoV-OC43, HCoV-229E, SARS, and MERS zoonotic coronaviruses. Remdesivir (GS-5734) is a monophosphoramidate prodrug of an adenosine analogue that is activated intra-cellularly to the main metabolite in plasma “GS-441524” which act mainly by interfering with the action of viral RNA-dependent RNA polymerase and escapes proofreading by viral exoribonuclease resulting reducing in viral RNA replication [1-4].

Warren, et al. [5] reported that remdesivir has an antiviral activity against multiple variants of Ebola virus and other filoviruses in cell-based assays. Nonhuman primates receiving intravenous remdesivir had persistent nucleoside triphosphate levels in peripheral blood mononuclear cells (half-life:14 hours) and distribution to sites of viral replication in the testes, eyes, and brain. In a rhesus monkey model of Ebola virus disease, once-daily remdesivir intravenous administration of 10 mg/kg for 12 days was associated with a great suppression of Ebola virus replication and therefore protected 100% of Ebola virus-infected animals against fatal disease. Treatment also improved the clinical and pathophysiological markers, even when treatments were started three days after virus exposure when systemic viral RNA was detected in two out of six treated animals. Warren et al suggested that remdesivir important post-exposure protection against Ebola virus disease in nonhuman primates.

Sheahan, et al. [6] showed that remdesivir can inhibit SARS-CoV and MERS-CoV replication in multiple in vitro systems, including primary human airway epithelial cell cultures with submicromolar IC50 values. Remdesivir can also inhibit bat CoVs, pre-pandemic bat CoVs, and circulating contemporary human CoV in primary human lung cells. In a mouse model of SARS-CoV pathogenesis, prophylactic and early therapeutic administration of remdesivir considerably decreased lung viral load and was associated with clinical improvement and also improved respiratory function.

Agostini, et al. [7] reported that remdesivir can effectively inhibit human and zoonotic coronaviruses in vitro and in a Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) mouse model. They also showed that remdesivir can inhibit Murine Hepatitis Virus (MHV) with similar 50% effective concentration values (EC50) as SARS-CoV and Middle East Respiratory Syndrome Coronavirus (MERS-CoV).

In animal experiment, Pedersen, et al. [8] studied the safety of remdesivir, and found it safe at a dose of 4.0 mg/kg S.C q24h for 12 weeks.

de Wit, et al. [9] described the prophylactic and therapeutic use of remdesivir in the treatment of a nonhuman primate “rhesus macaque” model of MERS-CoV infection. Prophylactic remdesivir was started 24 hours before inoculation, completely prevented MERS-CoV-induced clinical disease, potently inhibited MERS-CoV replication in respiratory tissues, and prevented the formation of lung lesions. Therapeutic remdesivir treatment started 12 hours post-inoculation was associated with an obvious clinical benefit, with a reduction in clinical signs, reduced virus replication in the lungs, and reduction of lung lesions, and its severity.

Wang, et al. [10] reported a randomised, double-blind, placebo-controlled, multicentre trial at ten hospitals in Hubei, China. The study included 237 adults with SARS-CoV-2 positive tests hospitalized within 12 days or less from the onset of symptoms and had oxygen saturation of 94% or less on room air or a ratio of arterial oxygen partial pressure to fractional inspired oxygen of 300 mm Hg or less, and had radiological evidence of pneumonia. 158 patients were to remdesivir intravenous remdesivir (200 mg on day 1 followed by 100 mg on days 2-10 in single daily infusions). 79 patients were treated with placebo infusions for 10 days. Concomitant use of lopinavir-ritonavir, interferons, and corticosteroids was allowed.

Remdesivir use was not associated with a statistically significant difference in time to clinical improvement (hazard ratio 1·23 [95% CI 0·87-1·75]), but patients treated with remdesivir had a numerically faster time to clinical improvement than patients treated with placebo. Adverse effects were observed in 102 (66%) of remdesivir-treated patients and 50 (64%) of placebo-treated patients. Remdesivir was stopped early because of adverse effects in 18 (12%) patients, and four (5%) patients stopped placebo early.

Beigel, et al. [11] reported a double-blind, randomized, placebo-controlled trial of treating adults hospitalized with Covid-19 with evidence of lower respiratory tract involvement with intravenous remdesivir. 538 patients were treated with remdesivir (200 mg loading dose on day 1, followed by 100 mg daily for up to 9 additional days). 521 patients were treated with placebo for up to 10 days. Remdesivir-treated patients had a median recovery time of 11 days (95% Confidence Interval [CI], 9 to 12), while patients in the placebo group had a median recovery time of 15 days (95% CI, 13 to 19) [Rate ratio for recovery, 1.32; 95% CI, 1.12 to 1.55; p <0.001]. Kaplan-Meier mortality by 14 days were 7.1% in remdesivir-treated patients, and 11.9% the placebo group (hazard ratio for death, 0.70; 95% CI, 0.47 to 1.04). Serious effects occurred in 114 of the 541 patients in the remdesivir and 141 in the placebo group. It’s considered remdesivir to be superior to placebo in shortening the time to recovery in adults hospitalized with Covid-19 who had lower respiratory tract infection. The currently, available evidence suggests that remdesivir can be useful in the treatment of Covid-19, but its use as a mono-therapy is far from being the ultimate therapy for Covid-19.

The recent evidence-based recommendation which was published in 9 languages [4,12-19] emphasized that until now, there is no single drug can result in a virological cure. However, lopinavir/ritonavir, remdesivir, azithromycin, and teicoplanin are possibly at the top of the list weapons of that have the potential to enable humans to win the fight against covid-19, but in condition that are used in suitable combinations. Chloroquine side effects include flue like febrile illness, shortness of breath and cardiomyopathy and therefore should be considered after lopinavir/ritonavir, remdesivir, and teicoplanin. Lopinavir/ritonavir was considered at the top of the list because it is more available than remdesivir in many countries of the world, and it has more known profile of toxicity and side effects.

  1. Al Mosawi AJ. Bat-Human Coronaviruses: A Global Health Problem and a Therapeutic Challenge. Journal of Medical Clinical Case Reports. 2020;2(2). 1-3. doi: 10.5281/zenodo.3878405
  2. Al Mosawi AJ. The Use of the Available Research Evidence to Crack the Padlock of Sars-CoV-2. Journal of Virology Research & Reports. 2020;1(1): 1-8. doi: 10. 5281/ zenodo.3970844
  3. Al Mosawi AJ. Bat-human coronaviruses: Keys to the therapeutic challenge. 1st ed. Saarbrücken; LAP Lambert Academic Publishing: 2020.
  4. Al Mosawi AJ. Bat-human Coronaviruses: Keys to The Therapeutic Challenge. 1st ed. Baghdad; Iraq Headquarter of Copernicus Scientists International Panel Publishing: 2020.
  5. Warren TK, Jordan R, Lo MK, Ray AS, Mackman RL, Soloveva V, Siegel D, Perron M, Bannister R, Hui HC, Larson N, Strickley R, Wells J, Stuthman KS, Van Tongeren SA, Garza NL, Donnelly G, Shurtleff AC, Retterer CJ, Gharaibeh D, Zamani R, Kenny T, Eaton BP, Grimes E, Welch LS, Gomba L, Wilhelmsen CL, Nichols DK, Nuss JE, Nagle ER, Kugelman JR, Palacios G, Doerffler E, Neville S, Carra E, Clarke MO, Zhang L, Lew W, Ross B, Wang Q, Chun K, Wolfe L, Babusis D, Park Y, Stray KM, Trancheva I, Feng JY, Barauskas O, Xu Y, Wong P, Braun MR, Flint M, McMullan LK, Chen SS, Fearns R, Swaminathan S, Mayers DL, Spiropoulou CF, Lee WA, Nichol ST, Cihlar T, Bavari S. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature. 2016 Mar 17;531(7594):381-5. doi: 10.1038/nature17180. Epub 2016 Mar 2. Erratum in: ACS Chem Biol. 2016 May 20;11(5):1463. PMID: 26934220; PMCID: PMC5551389.
  6. Sheahan TP, Sims AC, Graham RL, Menachery VD, Gralinski LE, Case JB, Leist SR, Pyrc K, Feng JY, Trantcheva I, Bannister R, Park Y, Babusis D, Clarke MO, Mackman RL, Spahn JE, Palmiotti CA, Siegel D, Ray AS, Cihlar T, Jordan R, Denison MR, Baric RS. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med. 2017 Jun 28;9(396):eaal3653. doi: 10.1126/scitranslmed.aal3653. PMID: 28659436; PMCID: PMC5567817.
  7. Maria LA, Erica LA, Amy CS, Rachel LG, Timothy PS, Xiaotao L, Everett CS, James BC, Joy YF, Robert J, Adrian SR, Tomas C, Dustin S, Richard LM, Michael OC, Ralph SB, Mark RD. Coronavirus susceptibility to the antiviral remdesivir (gs-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. mBio. 2018;9(2): e00221-18. PMID: 29511076. doi: 10.1128/ mBio. 00221-18
  8. Pedersen NC, Perron M, Bannasch M, Montgomery E, Murakami E, Liepnieks M, Liu H. Efficacy and safety of the nucleoside analog GS-441524 for treatment of cats with naturally occurring feline infectious peritonitis. J Feline Med Surg. 2019 Apr;21(4):271-281. doi: 10.1177/1098612X19825701. Epub 2019 Feb 13. PMID: 30755068; PMCID: PMC6435921.
  9. Emmie de W, Friederike F, Jacqueline C, Robert J, Atsushi O, Tina T, Dana S, Tomas C, Heinz F. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proc Natl Acad Sci USA. 2020;117(12): 6771-6776. PMID: 32054787. doi:10.1073/pnas.1922083117
  10. Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, Fu S, Gao L, Cheng Z, Lu Q, Hu Y, Luo G, Wang K, Lu Y, Li H, Wang S, Ruan S, Yang C, Mei C, Wang Y, Ding D, Wu F, Tang X, Ye X, Ye Y, Liu B, Yang J, Yin W, Wang A, Fan G, Zhou F, Liu Z, Gu X, Xu J, Shang L, Zhang Y, Cao L, Guo T, Wan Y, Qin H, Jiang Y, Jaki T, Hayden FG, Horby PW, Cao B, Wang C. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020 May 16;395(10236):1569-1578. doi: 10.1016/S0140-6736(20)31022-9. Epub 2020 Apr 29. Erratum in: Lancet. 2020 May 30;395(10238):1694. PMID: 32423584; PMCID: PMC7190303.
  11. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S, Lopez de Castilla D, Finberg RW, Dierberg K, Tapson V, Hsieh L, Patterson TF, Paredes R, Sweeney DA, Short WR, Touloumi G, Lye DC, Ohmagari N, Oh MD, Ruiz-Palacios GM, Benfield T, Fätkenheuer G, Kortepeter MG, Atmar RL, Creech CB, Lundgren J, Babiker AG, Pett S, Neaton JD, Burgess TH, Bonnett T, Green M, Makowski M, Osinusi A, Nayak S, Lane HC; ACTT-1 Study Group Members. Remdesivir for the Treatment of Covid-19 - Final Report. N Engl J Med. 2020 Oct 8:NEJMoa2007764. doi: 10.1056/NEJMoa2007764. Epub ahead of print. PMID: 32445440; PMCID: PMC7262788.
  12. Al-Mosawi AJ. Использование данных исследований для взлома замка SARS-CoV-2 (Russian edition) Sciencia Scripts: 2020.
  13. Al-Mosawi AJ. Utilização de provas de investigação para rachar o cadeado da SRA-CoV-2 (Portuguese edition). Edições Nosso Conhecimento: 2020.
  14. Al-Mosawi AJ. Użycie dowodów naukowych do złamania kłódki SARS-CoV-2 (Polish edition) Wnictwo Nasza Wiedza: 2020.
  15. Al-Mosawi AJ. Gebruik van onderzoeksmateriaal voor het kraken van het hangslot van SARS-CoV-2 (Dutch edition). Uitgeverij Onze kennis: 2020.
  16. Al-Mosawi AJ. Utilizzare le prove della ricerca per rompere il lucchetto della SARS-CoV-2 (Italian edition) Edizioni Sapien: 2020.
  17. Al-Mosawi AJ. Utilisation des résultats de la recherche pour briser le cadenas du SRAS-CoV-2 (French edition) Editions Notre Savoir: 2020.
  18. Al-Mosawi AJ. El uso de pruebas de investigación para romper el candado del SARS-CoV-2 (Spanish edition). Ediciones Nuestro Conocimiento: 2020.
  19. Al-Mosawi AJ. Verwendung von Forschungsergebnissen zum Knacken des Vorhängeschlosses von SARS-CoV-2 (German edition) Verlag Unser Vissen: 2020.

Content Alerts

SignUp to our
Content alerts.

Creative Commons License This work is licensed under a Creative Commons Attribution 4.0 International License.